Holly Sennett
Nurse Practitioner · Omaha, NENPI 1699923243
Payments from drug & device makers
Across 236 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$984
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$877
- Takeda Pharmaceuticals U.S.A., Inc.$469
- Johnson & Johnson$440
- Aimmune Therapeutics, Inc.$224
- Sanofi$196
- plus $1K from 28 others
What the payments were for
- Food & beverage$4,257100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $984 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 53 | $877 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $469 |
| Johnson & Johnson(2 entities) | 27 | $440 |
| Aimmune Therapeutics, Inc. | 2 | $224 |
| Sanofi | 9 | $196 |
| Hologic Sales And Service, LLC | 1 | $96 |
| Ironwood Pharmaceuticals, Inc | 5 | $95 |
| Nestle Healthcare Nutrition Inc. | 4 | $81 |
| Intercept Pharmaceuticals, Inc. | 4 | $66 |
| Solventum Corporation | 3 | $59 |
| KCI USA, Inc. | 2 | $52 |
| Lifenet Health | 2 | $48 |
| AstraZeneca | 3 | $47 |
| BD | 1 | $43 |
| Merck | 2 | $36 |
| Smith+Nephew | 1 | $34 |
| RTI Surgical, Inc | 2 | $34 |
| Zimmer Biomet | 1 | $34 |
| Medtronic | 2 | $33 |
| Iovance Biotherapeutics, Inc. | 1 | $33 |
| Conetic Solutions, Inc. | 2 | $32 |
| Davol Inc. | 2 | $32 |
| Teleflex LLC | 2 | $29 |
| Astellas Pharma US Inc | 1 | $26 |
| QOL Medical, LLC | 1 | $22 |
| Exact Sciences | 1 | $21 |
| Polynovo North America LLC | 1 | $20 |
| Convatec Inc. | 1 | $18 |
| Evoke Pharma, Inc. | 1 | $17 |
| Coloplast | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOWST$204
How this compares
$4,257 in reported general payments places this provider in the 90th percentile of 924 nurse practitioner providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 14 | $5,632 |
| Pantoprazole Sodium | 20 | $224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aimmune Therapeutics, Inc.Zenpep | $224 | $5,63214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 924 nurse practitioner providers in Nebraska.
Other nurse practitioner in Omaha
- Kristen HammesOmaha$899K
- Amy MuchowiczOmaha$78K
- Kari CunninghamOmaha$53K
- Laura DonovanOmaha$49K
- Kathleen HealeyOmaha$36K
- Katie RuchOmaha$26K
- Amanda GuggenmosOmaha$23K
- Amy YagerOmaha$15K
- Cara SchiesslerOmaha$14K
- Lindsay OneilOmaha$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.